Idecabtagene Vicleucel for Patients With NDMM and Suboptimal Responses to Frontline ASCT
July 14, 2025 • CAR-T Content Hub
Barry Paul, MD, Atrium Health Levine Cancer Institute, Charlotte, North Carolina, discusses research related to idecabtagene vicleucel treatment for patients with newly diagnosed multiple myeloma and suboptimal responses to frontline autologous stem cell transplant. The results demonstrate a high progression-free survival rate and manageable toxicity. Notably, these results were also seen in patients who did not receive lenalidomide maintenance therapy.
